Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
2.740
-0.080 (-2.84%)
At close: May 30, 2025, 4:00 PM
2.680
-0.060 (-2.18%)
After-hours: May 30, 2025, 6:24 PM EDT
Voyager Therapeutics Employees
Voyager Therapeutics had 172 employees as of December 31, 2024. The number of employees increased by 10 or 6.17% compared to the previous year.
Employees
172
Change (1Y)
10
Growth (1Y)
6.17%
Revenue / Employee
$389,291
Profits / Employee
-$492,401
Market Cap
151.62M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
VYGR News
- 15 days ago - Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication - GlobeNewsWire
- 24 days ago - Voyager Reports First Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 4 weeks ago - Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewsWire
- 2 months ago - Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - GlobeNewsWire
- 2 months ago - Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewsWire
- 3 months ago - Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast - GlobeNewsWire
- 3 months ago - Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease - GlobeNewsWire